Articles

  • 1 week ago | tradingview.com | Stephen Nakrosis

    By Stephen NakrosisGSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule. Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday.

  • 1 week ago | tradingview.com | Stephen Nakrosis

    Virginia Housing Development Authority Offering $210 Million in Mortgage BondsThe Virginia Housing Development Authority is offering $210 million in commonwealth mortgage bonds, with proceeds going to finance mortgage loans. The bonds will be issued in two tranches — a tax-exempt $70 million 2024 Series F-Non-AMT, Subseries F-1 issuance, and a $140 million 2023 Series B-taxable issuance. The bonds were rated Aaa by Moody's and AAA by S&P, according to offering documents on MuniOS.

  • 1 week ago | wsj.com | Stephen Nakrosis

    April 14, 2025 4:50 pm ETLowe’s said it agreed to acquire Artisan Design Group from private equity firm Sterling Group for $1.33 billion. The home improvement company said it will finance the acquisition with cash on hand. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

  • 1 week ago | tradingview.com | Stephen Nakrosis

    By Stephen NakrosisLowe's said it agreed to acquire Artisan Design Group from private equity firm Sterling Group for $1.33 billion. The home improvement company said it will finance the acquisition with cash on hand. Artisan Design Group is headquartered in Dallas, and operates 132 distribution, design and service facilities. The group coordinates installation through over 3,200 personnel across 18 states, Sterling said. The group recorded fiscal 2024 revenue of about $1.8 billion.

  • 1 week ago | tradingview.com | Stephen Nakrosis

    FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some CarcinomasBMYBristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma. Opdivo, or nivolumab, plus Yervoy, or ipilimumab, was approved as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma, the company said Friday. HCC is the most common primary liver cancer, according to the company.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map